Fortress Biotech, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Fortress Biotech, Inc. (FBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-31
- Fortress Biotech, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.50%.
- Fortress Biotech, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.90%, a 280.00% decline from fiscal 2022.
- Fortress Biotech, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 0.50%, a 83.33% decline from fiscal 2021.
- Fortress Biotech, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 3.00%, a 200.00% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -0.50% 10-K · filed 2026-03-31 | |
| 2023-12-31 | -0.90% 10-K · filed 2025-03-31 | 0.90% 10-K · filed 2024-03-28 |
| 2022-12-31 | 0.50% 10-K · filed 2024-03-28 | 1.00% 10-K · filed 2023-03-31 |
| 2021-12-31 | 3.00% 10-K · filed 2023-03-31 | |
| 2020-12-31 | 1.00% 10-K · filed 2022-03-28 | |
| 2019-12-31 | 0.00% 10-K/A · filed 2021-04-09 | |
| 2018-12-31 | 0.00% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 2.00% 10-K · filed 2019-03-18 | |
| 2016-12-31 | 4.00% 10-K · filed 2018-03-16 | |
| 2015-12-31 | 0.00% 10-K · filed 2018-03-16 | |
| 2014-12-31 | 1.00% 10-K · filed 2017-03-16 | |
| 2013-12-31 | 2.00% 10-K · filed 2016-03-15 | -2.00% 10-K · filed 2014-03-14 |
| 2012-12-31 | 2.00% 10-K · filed 2015-03-16 | -2.00% 10-K · filed 2013-03-18 |
| 2011-12-31 | -21.00% 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |